First-time use of bevacizumab for metastatic hepatocellular carcinoma in a HIV/HBV coinfected patient. A case report

I. G. Baraboutis, G. Charitsis, V. Papastamopoulos, L. Lekakis, M. M. Vaslamatzis, A. T. Skoutelis

Research output: Contribution to journalArticle

Abstract

A case of a HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma (HCC) with multiple metastasis is presented. Systemic chemotherapy combined with use of bevacizumab (anti-VEgF monoclonal antibody) was without effect and the patient succumbed to his disease within weeks. Relatively recent data indicate that HCC may be extremely aggressive in HIV/HBV or HIV/HCV coinfected patients with younger age at presentation, shorter evolution time, a more advanced stage at presentation with higher rates of extrahepatic-extranodal metastases and, finally, a reduced survival rate as compared with HIV-negative patients. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV infected patients.

Original languageEnglish (US)
Pages (from-to)634-636
Number of pages3
JournalArchives of Hellenic Medicine
Volume25
Issue number5
StatePublished - Sep 1 2008
Externally publishedYes

Keywords

  • Anti-VEGF
  • Bevacizumab
  • HIV/HBV coinfection
  • Metastatic hepatocellular carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'First-time use of bevacizumab for metastatic hepatocellular carcinoma in a HIV/HBV coinfected patient. A case report'. Together they form a unique fingerprint.

  • Cite this

    Baraboutis, I. G., Charitsis, G., Papastamopoulos, V., Lekakis, L., Vaslamatzis, M. M., & Skoutelis, A. T. (2008). First-time use of bevacizumab for metastatic hepatocellular carcinoma in a HIV/HBV coinfected patient. A case report. Archives of Hellenic Medicine, 25(5), 634-636.